RSV, Pfizer
U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO® (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine,
Pfizer, Starboard Value
In collaboration with Gavi, Pfizer has been instrumental in expanding access to lifesaving vaccines in low- and ...
Michela Tindera But despite losing Read and D’Amelio’s support, Starboard is still pushing ahead with its campaign. Yesterday, October 22nd, at an activist investor conference in New York, Starboard ...
Barely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value ...
The activist investor claims Pfizer failed to capitalize on the windfall earned from its COVID-19 vaccine and, in the process, destroyed tens of billions of dollars in market value.
A group of U.S. senators are digging into the direct-to-consumer telehealth platforms launched by Eli Lilly and Pfizer this ...
The U.S. Food and Drug Administration has asked a federal judge in Texas to throw out a public records lawsuit related to ...
As a long-term holding, Pfizer should benefit from demographic trends driving increased healthcare spending globally. The ...
Investment firm Starboard Value, which has launched an activist campaign against Pfizer (NYSE:PFE), upped the ante on the New ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback